TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients
Brief Summary: Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.


Options:
A: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: Observational; Type: N/A; Interventions: N/A
D: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients
Brief Summary: Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.


Options:
A: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A
B: Arm Label: TIP (Tobramycin Inhalation Powder); Type: EXPERIMENTAL; Interventions: Drug: Tobramycin Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tobramycin Inhalation Powder; Assigned to Arm(s): TIP (Tobramycin Inhalation Powder) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo three times a day (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times a day (TID) | Arm Label: AZLI 75 mg three times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times a day (TID); Assigned to Arm(s): AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: Placebo three times a day (TID); Assigned to Arm(s): Placebo three times a day (TID)
D: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief Summary: The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1).


Options:
A: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: IMA-026 | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: IMA-026; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
C: Arm Label: huMAb OX40L; Type: EXPERIMENTAL; Interventions: Drug: huMAb OX40L | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: huMAb OX40L; Assigned to Arm(s): huMAb OX40L | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Arm Label: Reslizumab - 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management
Brief Summary: The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).


Options:
A: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
B: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
C: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Procedure: pars plana vitrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pars plana vitrectomy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: pars plana vitrectomy; Assigned to Arm(s): A, B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management
Brief Summary: The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).


Options:
A: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
B: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
C: Arm Label: intravitreal bevacizumab injections and then rescue; Type: ACTIVE_COMPARATOR; Interventions: Drug: receive 4 monthly IVB injections and then rescue IVB | Arm Label: PRP group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRP group | Arm Label: IVB injections and a modified laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: IVB injections and a modified laser | Intervention Type: DRUG; Name: receive 4 monthly IVB injections and then rescue IVB; Assigned to Arm(s): intravitreal bevacizumab injections and then rescue | Intervention Type: DRUG; Name: PRP group; Assigned to Arm(s): PRP group | Intervention Type: DRUG; Name: IVB injections and a modified laser; Assigned to Arm(s): IVB injections and a modified laser
D: Arm Label: Arm A: 0.3 mg Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: Arm B: 1.5 mg Faricimab; Type: EXPERIMENTAL; Interventions: Drug: Faricimab | Arm Label: Arm C: 6 mg Faricimab; Type: EXPERIMENTAL; Interventions: Drug: Faricimab | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): Arm B: 1.5 mg Faricimab, Arm C: 6 mg Faricimab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Arm A: 0.3 mg Ranibizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management
Brief Summary: The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).


Options:
A: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Procedure: pars plana vitrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pars plana vitrectomy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: pars plana vitrectomy; Assigned to Arm(s): A, B
C: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
D: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management
Brief Summary: The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).


Options:
A: Arm Label: Panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Panretinal photocoagulation | Arm Label: Bevacizumab + Panretinal Photocoagulation (PRP); Type: EXPERIMENTAL; Interventions: Procedure: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab | Intervention Type: PROCEDURE; Name: Panretinal photocoagulation; Assigned to Arm(s): Panretinal photocoagulation | Intervention Type: PROCEDURE; Name: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab; Assigned to Arm(s): Bevacizumab + Panretinal Photocoagulation (PRP)
B: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
C: Arm Label: Placebo first (scheme 2); Type: OTHER; Interventions: Drug: potassium diclofenac | Arm Label: Diclofenac first (scheme 1); Type: OTHER; Interventions: Drug: potassium diclofenac | Intervention Type: DRUG; Name: potassium diclofenac; Assigned to Arm(s): Diclofenac first (scheme 1), Placebo first (scheme 2)
D: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224)
Brief Summary: The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate 800 mg/d | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate 1,200 mg/d | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin 300 mg/d | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin 300 mg/d; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Carisbamate 800 mg/d; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Carisbamate 1,200 mg/d; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 004
C: Arm Label: Pregablain CR tablet 82.5 to 660mg; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregablain CR tablet 82.5 to 660mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients
Brief Summary: The purpose of this study is to determine whether an intravenous salt solution called "Plasmalyte" causes less abnormality of the body's acid levels than a solution called "Normal Saline."


Options:
A: Arm Label: multiple electrolyte solution; Type: EXPERIMENTAL; Interventions: Drug: multiple electrolyte solution | Arm Label: saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: multiple electrolyte solution; Assigned to Arm(s): multiple electrolyte solution | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
B: Arm Label: Plasmalyte; Type: EXPERIMENTAL; Interventions: Other: Plasmalyte A | Arm Label: Normal Saline; Type: ACTIVE_COMPARATOR; Interventions: Other: Normal Saline | Intervention Type: OTHER; Name: Plasmalyte A; Assigned to Arm(s): Plasmalyte | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Normal Saline
C: Arm Label: Phase A1: Plasmalyte; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crystalloid | Arm Label: Phase A2: 0.9% Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crystalloid | Arm Label: Phase B1: PlasmaVolume; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colloid | Arm Label: Phase B2: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colloid | Intervention Type: DRUG; Name: Crystalloid; Assigned to Arm(s): Phase A1: Plasmalyte, Phase A2: 0.9% Saline | Intervention Type: DRUG; Name: Colloid; Assigned to Arm(s): Phase B1: PlasmaVolume, Phase B2: Voluven
D: Arm Label: 0.9% sodium chloride; Type: ACTIVE_COMPARATOR; Interventions: Other: 0.9% sodium chloride | Arm Label: Physiologically balanced fluid; Type: ACTIVE_COMPARATOR; Interventions: Other: Physiologically balanced fluid | Intervention Type: OTHER; Name: 0.9% sodium chloride; Assigned to Arm(s): 0.9% sodium chloride | Intervention Type: OTHER; Name: Physiologically balanced fluid; Assigned to Arm(s): Physiologically balanced fluid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO 2)
Brief Summary: To determine if the Trevo Retriever is as good or better than the Merci Retriever in restoring blood flow to the brain of a patient experiencing an acute ischemic stroke in a large vessel.


Options:
A: Arm Label: Solitaire™ FR device; Type: N/A; Interventions: Device: Solitaire™ FR device | Intervention Type: DEVICE; Name: Solitaire™ FR device; Assigned to Arm(s): Solitaire™ FR device
B: Arm Label: Merci Retriever; Type: ACTIVE_COMPARATOR; Interventions: Device: Mechanical Thrombectomy | Arm Label: Trevo Stentriever; Type: EXPERIMENTAL; Interventions: Device: Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Mechanical Thrombectomy; Assigned to Arm(s): Merci Retriever, Trevo Stentriever
C: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
D: Arm Label: 1 Mechanical Embolectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Merci Retriever and Penumbra System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Merci Retriever and Penumbra System; Assigned to Arm(s): 1 Mechanical Embolectomy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program: a Randomized Placebo Controlled Clinical Trial
Brief Summary: Background: Exercise, weight loss, and dietary supplementation of glucosamine and chondroitin (GC) have been reported to improve functional capacity in individuals with knee osteoarthritis (OA). The purpose of this study was 1.) to determine whether women with knee OA who follow a higher protein diet observe more favorable changes in body composition and/or markers of health compared to those following a standard higher carbohydrate-based diet; and, 2.) to determine whether dietary supplementation of glucosamine and chondroitin during a weight loss and fitness program lessens symptoms of pain, improves functional capacity, and/or promotes greater health benefits in women with knee OA. It was hypothesized that both groups would experience beneficial changes in body mass, body composition, and markers of health. However, greater benefits would be observed in those following a higher protein diet while supplementing the diet with glucosamine and chondroitin.


Options:
A: Arm Label: Chondroitin 4&6 sulfate (Condrosulf); Type: ACTIVE_COMPARATOR; Interventions: Drug: Chondroitin 4&6 sulfate (Condrosulf) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Chondroitin 4&6 sulfate (Condrosulf); Assigned to Arm(s): Chondroitin 4&6 sulfate (Condrosulf) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Diet, Other: Exercise | Arm Label: Active Supplement; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet, Other: Exercise | Intervention Type: OTHER; Name: Diet; Assigned to Arm(s): Active Supplement, Placebo | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Active Supplement, Placebo
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Chondroitin sulphate | Intervention Type: DRUG; Name: Chondroitin sulphate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: glucosamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chondroitin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glucosamine and chondroitin sulfate combined; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): N/A

Answer: B